Home Blog Page 66

Fortis Healthcare Board Approves Unaudited Results for Quarter and Six Months Ended September 30, 2025

Fortis Healthcare’s Board has approved the unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025. Standalone revenue from operations stood at ₹45,581 lacs for the quarter. Consolidated revenue from operations was ₹233,144 lacs for the same period. The board has co-operated with relevant regulatory authorities and has also initiated necessary actions for legal rights, as needed.

Financial Performance

For the quarter ended September 30, 2025, Fortis Healthcare reported the following standalone results:

  • Revenue from operations: ₹45,581 lacs
  • Other income: ₹9,242 lacs
  • Total income: ₹54,823 lacs
  • Net profit: ₹12,509 lacs

The consolidated results for the quarter ending September 30, 2025 are:

  • Revenue from operations: ₹233,144 lacs
  • Other income: ₹2,258 lacs
  • Total income: ₹235,402 lacs
  • Net profit: ₹32,882 lacs

Segment Reporting

The segment results for the quarter ending September 30, 2025 are broken down as follows:

  • Healthcare: Revenue: ₹197,382 lacs, Profit: ₹37,566 lacs
  • Diagnostics: Revenue: ₹39,963 lacs, Profit: ₹7,483 lacs

Regulatory & Legal Matters

The board has addressed concerns from investigations by the Serious Fraud Investigation Office (SFIO) and is fully cooperating. They have undertaken reviews regarding historical transactions. Additionally, all required findings have been submitted to regulatory authorities, and legal proceedings have been initiated where action is recommended by legal counsel. The group believes it maintains a strong case on merits and further impact on financial results isn’t expected to be material.

Other Key Highlights

  • On October 16, 2025, it completed the Fortis and Malar Open Offers.
  • Pursuant to an order dated September 16, 2025, it deposited ₹55.37 Crores towards the license fee for the ‘Fortis’ trademark.
  • During the quarter, Fortis entered into an operations and maintenance service agreement with Gleneagles Healthcare India Private Limited for five hospitals and one clinic which is effective from July 23, 2025.

Source: BSE

Fortis Healthcare Board Approves Unaudited Results for Quarter Ended September 2025

Fortis Healthcare Limited has announced the approval of its unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025. Key highlights include a consolidated total income of ₹235.40 crore for the quarter and a net profit of ₹32.88 crore. The board has taken steps to recover dues from erstwhile promoters, but investigations are still ongoing.

Financial Performance

The Board of Directors has approved the unaudited standalone and consolidated financial results for Q2 2025-26. Here are some of the key financial figures:

  • Consolidated Total Income: ₹235.40 crore
  • Consolidated Net Profit: ₹32.88 crore

Segmental Performance

A breakdown of the total value of sales and services (revenue from operations) across segments reveals:

  • Healthcare: ₹197.38 crore
  • Diagnostics: ₹39.96 crore

Ongoing Investigations and Matters

The company continues to address ongoing investigations involving erstwhile promoters, and is cooperating with regulatory bodies. Fortis is undertaking measures for recovery and compliance.

Additional Information

The earnings per equity share for continuing operations (not annualised) are:

  • Basic earnings per share: ₹4.26
  • Diluted earnings per share: ₹4.26

The company entered into an operation and maintenance service agreement with Gleneagles Healthcare India Private Limited effective July 23, 2025, and a sub-lease agreement with R.R Lifesciences Pvt. Ltd effective September 1, 2025.

Auditor’s Report

The limited review report filed by the auditors remains unmodified.

Security Coverage

The security cover ratio for the non-convertible debentures is 1.24 on book value and 1.49 on market value. The company continues to adhere to all financial and non-financial covenants as stipulated in their Debenture Trust Deed.

Source: BSE

Biocon Board Approves Unaudited Financial Results and CCD Acquisition

Biocon’s Board of Directors has approved the unaudited financial results for the quarter and half-year ended September 30, 2025. Additionally, the board approved the early full redemption of 50,000 Non-Convertible Debentures (NCDs) and the acquisition of Compulsorily Convertible Debentures (CCDs) of Biocon Biologics Limited from ESOF III Investment Fund and EAAA India Alternatives Limited for ₹300 Crores. The board also approved the issuance of Commercial Papers up to ₹550 Crores.

Financial Results Overview

Biocon’s Board of Directors has officially approved the unaudited financial results for the quarter and half-year which ended on September 30, 2025. These results were reviewed during a board meeting held on November 11, 2025, according to the company’s official announcement. The results have been prepared in accordance with the Indian Accounting Standard (Ind-AS).

Early Redemption of NCDs

The board approved the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). The debentures have a face value of ₹1,00,000 each. In total, the aggregate value amounts to ₹500 Crores. These NCDs were initially issued and allotted on a private placement basis on May 19, 2023. The redemption is conditional on receipt of necessary approvals and consents by January 31, 2026.

Acquisition of CCDs

Biocon will acquire 1,06,86,044 Unlisted, Secured, Compulsorily Convertible Debentures (‘CCDs’) of Biocon Biologics Limited (‘BBL’). The acquisition comes from ESOF III Investment Fund and EAAA India Alternatives Limited. Collectively, this is referred to as “Edelweiss.” The face value of each CCD is ₹10. The aggregate amount is ₹300 Crores and the deal is expected to occur on or before January 30, 2026, subject to approvals.

Commercial Paper Issuance

The Board also approved the issuance of Commercial Papers (CPs) for an amount not exceeding ₹550 Crores. This issuance will occur in one or more tranches through private placement.

Board Meeting Conclusion

The board meeting commenced at 4:30 P.M. and concluded at 5:45 P.M. on November 11, 2025, after which the results and decisions were formally announced.

Source: BSE

Biocon Board Approves Quarterly Results, Non-Convertible Debenture Redemption

Biocon’s Board of Directors has approved the unaudited financial results for Q2 2025-26. The board also approved early redemption of 50,000 unlisted, secured, redeemable Non-Convertible Debentures (NCDs) aggregating to ₹500 Crores, subject to approvals by January 31, 2026. Additionally, the company will acquire Compulsorily Convertible Debentures of Biocon Biologics Limited from Edelweiss for ₹300 Crores.

Financial Results Highlights

The Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025 (Q2 2025-26). Key figures from the standalone results include:

  • Revenue from operations: ₹5,833 million
  • Total income: ₹7,171 million
  • Net Profit: ₹709 million

Non-Convertible Debenture Redemption

The board has approved the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs) with a face value of ₹1,00,000 each, aggregating to ₹500 Crores. The redemption is subject to the receipt of necessary approvals and/or consents on or before January 31, 2026. These NCDs were initially issued on May 19, 2023, on a private placement basis.

Acquisition of Convertible Debentures

Biocon will acquire 1,06,86,044 unlisted, secured, Compulsorily Convertible Debentures (CCDs) of Biocon Biologics Limited (BBL) from ESOF III Investment Fund and EAAA India Alternatives Limited (Edelweiss). The face value of the CCDs is ₹10 each, aggregating to ₹300 Crores. This acquisition is expected to be completed on or before January 30, 2026, subject to necessary approvals.

Commercial Paper Issuance

The company plans to issue Commercial Papers up to an amount not exceeding ₹550 Crores in one or more tranches on a private placement basis.

Source: BSE

Fortis Healthcare Board Approves Unaudited Financial Results for Q2 2026

Fortis Healthcare Limited’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025. Revenue from operations stood at ₹45,581 million for the quarter. The board also authorized a new operation and maintenance service deal with Gleneagles Healthcare India Private Limited, effective July 23, 2025, to oversee operations of five hospitals and one clinic.

Financial Performance Highlights

The Board of Directors of Fortis Healthcare Limited has officially approved the unaudited standalone and consolidated financial results for Q2 2026. Key financial figures include:

  • Revenue from Operations (Standalone):₹45,581 million for the quarter.
  • Total Income (Standalone):₹54,823 million for the quarter.
  • Net Profit (Standalone):₹12,509 million for the quarter.
  • Total Comprehensive Income (Standalone):₹12,504 million for the quarter.
  • Revenue from Operations (Consolidated):₹233,144 million for the quarter.
  • Total Income (Consolidated):₹235,402 million for the quarter.
  • Net Profit (Consolidated):₹32,882 million for the quarter.
  • Total Comprehensive Income (Consolidated):₹33,508 million for the quarter.

Strategic Business Decisions

In addition to the financial results, the board has sanctioned several key strategic initiatives:

  • Entered into an operation and maintenance service agreement with Gleneagles Healthcare India Private Limited, effective July 23, 2025, to manage the operations of five hospitals and one clinic.
  • International Hospital Limited (IHL) has executed a sub-lease agreement with R.R Lifesciences Pvt. Ltd (RRLPL) for sub leasing of Hospital land, building and equipment to IHL situated at Gautam Buddha Nagar, Greater Noida, effective September 1, 2025 and operations has commenced.

Ongoing Legal and Regulatory Matters

The company continues to address legacy legal and regulatory challenges, including investigations by the Serious Fraud Investigation Office (SFIO) and matters related to erstwhile promoters. Fortis maintains a strong commitment to cooperating with regulatory authorities and pursuing legal recourse where appropriate. Specifically, Fortis is diligently working to recover funds and ensure compliance with regulatory directives while safeguarding shareholder interests.

Source: BSE

PTC India Investor Presentation on Financial Results – Q2 & H1 FY 2025-26

PTC India has released its investor presentation for the financial results of Q2 and H1 FY 2025-26. The presentation highlights the company’s financial performance, business overview, and future strategies. Key figures include total revenue from operations, profit after tax, and trading volumes, alongside a detailed analysis of market trends and operational efficiencies.

Q2FY26 vs Q2FY25: Key Financial Highlights

PTC India’s performance in Q2FY26 compared to Q2FY25 reveals significant growth:

  • Total Revenue from Operations: Increased from ₹4,885.22 Cr to ₹5,458.73 Cr.
  • PAT from Continuing Operations: Rose from ₹162.78 Cr to ₹222.05 Cr.

Trading and Operational Performance

The company demonstrated improvements in trading and operational efficiency:

  • Trading Volume: Increased by 9%.
  • Operational Income: Grew by 11%, from ₹123.18 Cr to ₹136.91 Cr.
  • Consultancy Income: Increased by 17%.
  • Trading Margin: Improved by 11%, reaching ₹96.40 Cr.

H1-FY26 vs H1-FY25: Key Financials

A comparison of H1-FY26 with H1-FY25 shows the following:

  • Trading Volume: Increased by 11%, reaching 49,220 MU.
  • Operational Income: Decreased slightly by 1% to ₹248.08 Cr.
  • Consulting Income: Increased by 1%, reaching ₹21.96 Cr.
  • Trading Margin: Increased by 10% to ₹174.01 Cr.

Company Overview

PTC India is focused on power trading, aiming to develop a vibrant power market and correct market distortions. The company’s mission involves promoting power trading, developing market-based investments, facilitating power project development, and promoting power exchange with neighboring countries.

Operational Data and Portfolio

  • PTC India manages a portfolio of more than 7500 MW of operating Long Term (LT) & Medium Term (MT) contracts.
  • Hydro-based projects comprise 46% of the total Power Purchase Agreements (PPA).
  • Renewable projects, including hydro, constitute 58% of the operating PPA portfolio.

Business Initiatives

PTC India is involved in various initiatives, including:

  • Power Purchase Agreements (PPA) for solar power.
  • Memorandum of Understanding (MoU) with the Indian Port Association (IPA) for green energy transition.
  • Overseas consultancy services for power cost optimization.

Trading Market Dynamics

Key aspects of the Indian power trading market include operations through power exchanges, green power trading, and regulatory oversight by the Central Electricity Regulatory Commission (CERC).

Source: BSE

Adani Enterprises Board Approves Rights Issue Record Date

Adani Enterprises Limited has announced the record date for its upcoming rights issue as November 17, 2025. The company aims to raise up to ₹25,000 crore through this issue. The Rights Issue Committee has approved the terms, offering rights equity shares at ₹1,800 per share, including a premium of ₹1,799. Existing shareholders will be entitled to 3 Rights Equity Shares for every 25 fully paid-up Equity Shares held.

Rights Issue Details

Adani Enterprises Limited has finalized key details regarding its rights issue, which aims to raise up to ₹25,000.00 crore. The company will issue partly paid-up equity shares with a face value of ₹1 each.

Key Terms Approved

The Rights Issue Committee of the Board has approved the following:

Instrument:

Partly paid-up equity shares of face value of ₹1 each.

Total Number of Shares:

13,85,01,687 Rights Equity Shares, aggregating to ₹ 24,930.30 crores (assuming full subscription).

Price:

₹ 1,800.00 per Rights Equity Share (including a premium of ₹ 1,799.00 per Rights Equity Share).

Record Date:

Monday, November 17, 2025.

Shareholding Structure

Prior to Rights Issue:

1,15,41,80,729 equity shares

Post Rights Issue:

1,29,26,82,416 equity shares (assuming full subscription).

Rights Entitlement

The rights entitlement ratio is set at 3 Rights Equity Shares for every 25 fully paid-up Equity Shares held on the record date. The ISIN for Rights Entitlement is INE423A20016.

Source: BSE

Triveni Engineering H1 FY26 Earnings Call Transcript Highlights

Triveni Engineering reported strong H1 FY26 results with revenue up by 18.4% to over ₹3,300 crore. PBT reached ₹32 crore, a notable increase from ₹11.5 crore in the prior year. The company anticipates moderate sugar prices driven by potential export allowances and sugarcane diversions for ethanol production. Triveni also highlights improvements in distillery operations and a healthy performance in its engineering business. The business expects continued growth and improved performance for the rest of the year.

Financial Performance Overview

Triveni Engineering & Industries Limited announced its Q2 and H1 FY26 earnings, highlighting the following:

  • H1 FY26 Revenue: Increased by 18.4% to over ₹3,300 crore.
  • PBT: Stood at ₹32 crore compared to ₹11.5 crore in the prior year.
  • PAT: Reached ₹23.5 crore against ₹8.6 crore in the previous corresponding period.

Sugar Business

The sugar business saw revenue increase of 22% in H1, backed by a 14% rise in sugar dispatches and a 4% increase in realisations. For Q2, revenues rose by 27% driven by a 15% volume growth and 5% in realisations.

The company’s sugar inventory stood at 16.9 lakh quintals valued at ₹37.4 per kilo at the end of September. Triveni expects a domestic production of about 31 million tonnes, with sales of approximately 28 million tonnes and closing stock of about 7 million tonnes. This forecast accounts for a diversion of 3.25 million tonnes of sugar into ethanol and approximately 2 million tonnes of exports.

Alcohol Business

Alcohol sales for the quarter were down by 6%, due to supply chain issues. Ethanol constituted 92% of alcohol sales in Q2. Triveni also mentioned a significant improvement in profitability due to correction of input prices, particularly maize. OMCs have secured almost the entire quantity in cycle 1 for ESY 2025-2026.

Power Transmission Business

The power transmission business experienced a subdued order book during the quarter, but the company anticipates achieving robust double-digit growth in order booking, turnover, and profitability for this fiscal year. PBT margins have improved by over 400 basis points due to product mix and cost optimization.

The business has also secured 9 new OEM customers during the first half of FY26. The business is looking at the Indian market and foresees strong investment demand and manufacturing.

Water Business

Order booking of ₹1,520 crore was achieved. Cost reductions and maximizing profitability remain top priorities. New projects in recycle, reuse and Zero Liquid Discharge are being tendered for.

Scheme of Arrangement

The proposed amalgamation with SSEL and the demerger of the Power Transmission business has been approved by the stock exchanges. Meetings of stakeholders under the NCLT process have been scheduled for the end of November and early December for the two companies.

Source: BSE

PTC India Enters Joint Venture with NLC India Renewables for Green Energy Projects

PTC India has approved a Joint Venture Agreement with NLC India Renewables Limited to explore green energy projects. The collaboration aims to develop projects up to 2000 MW, including solar, wind, hydro, and battery storage, across India. NLC India Renewables will hold 74%, while PTC India will hold 26%. This partnership seeks to enhance trading portfolio and advisory services, promoting long-term sustainability.

Joint Venture for Green Energy Development

PTC India has approved entering a Joint Venture Agreement with NLC India Renewables Limited to explore opportunities in green energy. This announcement was made on November 11, 2025. The joint venture aims to develop Green Energy Projects across India.

Project Details and Scope

The collaboration will focus on projects with a capacity of up to 2000 MW. This includes a variety of renewable energy sources such as solar, wind, hydro, and battery storage systems. The projects will be developed on a pan-India basis in a phased manner. NLC India Renewables will hold a 74% stake, while PTC India will hold a 26% stake.

Rationale and Expected Benefits

The JV company is expected to strategically expand in the renewable assets. This will enhance the trading portfolio and consultancy/advisory services, contributing to long-term sustainability and a green growth trajectory.

Source: BSE

PTC India Board Approves Director Re-appointments and Appointments

PTC India’s Board of Directors has approved the re-appointment of Shri Prakash Mhaske as a Non-Executive Independent Director for a second term of three years starting January 16, 2026. The board also approved the appointment of Shri Sukhdev Singh as an Additional and Independent Director for three years effective November 11, 2025. Both appointments are subject to shareholder approval.

Director Re-appointment

The Board has approved the re-appointment of Shri Prakash Mhaske (DIN: 08512385) as a Non-Executive Independent Director. This second term will span three years, commencing on January 16, 2026. The re-appointment is contingent upon the approval of the company’s shareholders.

New Independent Director Appointment

Shri Sukhdev Singh (DIN: 03288811), a retired IAS officer (1987 Batch), has been appointed as an Additional Director and designated as an Independent Director. His term will be for three years, effective from November 11, 2025, also subject to shareholder approval.

Shri Prakash Mhaske’s Background

Shri Prakash Mhaske, aged 64, holds a Bachelor of Engineering degree. He previously served as Chairman of the Central Electricity Authority, bringing significant strategic leadership and technical expertise.

Shri Sukhdev Singh’s Background

Shri Sukhdev Singh is a 1987-batch IAS officer (Retd.) and holds a B.E. (Mechanical) degree. Throughout his career, he served in several senior positions, including Chief Secretary of Jharkhand.

Source: BSE